Biopharma Companies

Supporting the biopharma industry as it is develops and launches the most cutting edge innovation in Precision Medicine

 

From cell and gene therapies to antibody-drug conjugates, the biopharma industry is in an era of unprecedented innovation. However, companies must grapple with complexities around which partnerships to strike to access the data necessary to be a leader in Precision Medicine, how to navigate regional and country nuances related to areas such as reimbursement and availability of diagnostic tests, while driving organizational changes needed to be successful in this innovative field. KPMG has built a unique Precision Medicine offering which combines our proprietary Precision Medicine Insights database, our worldwide experience base, as well as our commercial launch, transaction assessment, and performance improvement offerings to transform the Precision Medicine businesses of our biopharma clients.


Example case studies

To understand more about the full suite of transformative non-deal and deal work we do with biopharma companies, please contact us.


Team & Contacts

Kristin C. Pothier

Kristin C. Pothier

Global & National, HCLS Deal Advisory & Strategy Leader, KPMG US

+1 617 549 2779
Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419
Varun Renjen, MD

Varun Renjen, MD

Managing Director, Life Sciences Deal Advisory and Strategy, KPMG US

+1 973-467-9650
Puja Ghelani

Puja Ghelani

Director, Healthcare and Life Sciences Strategy, KPMG US

+1 918-845-2389